KPV: The Tripeptide Anti-Inflammatory Story
KPV is a three-amino-acid peptide — lysine-proline-valine — that constitutes the C-terminal fragment of alpha-MSH. It carries much of the anti-inflammatory activity of the parent without the melanocortin-receptor effects on pigmentation. The mechanism story is interesting; the human evidence base is small.
KPV is one of the smallest bioactive peptides studied for inflammation.
KPV is the (11-13) fragment of alpha-MSH.
anti-inflammatory effect appears to be melanocortin-receptor independent, distinguishing it from PT-141.
no approved medicinal indications in major jurisdictions.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Animal and cell-line studies report anti-inflammatory effects across multiple tissue models — skin, gut, eye — that appear independent of melanocortin receptor signalling. The mechanism is not fully resolved. Human trial evidence is small and concentrated in specific contexts (some gut inflammation studies, topical applications).
Three amino acids with a real anti-inflammatory signature in animal models. The translation to human clinical evidence is still in its early chapters.
What it is
Alpha-MSH is a 13-amino-acid melanocortin peptide with well-established anti-inflammatory effects across multiple tissue models. KPV — its C-terminal tripeptide — retains much of the parent's anti-inflammatory activity while lacking the melanocortin-receptor effects (pigmentation, appetite modulation) attributed to the full peptide.
The mechanism is incompletely understood. KPV does not appear to act primarily through melanocortin receptors; proposed routes include intracellular delivery and direct interference with NF-kB and other pro-inflammatory transcription factors.
The published literature covers gut inflammation models, skin applications, and ocular inflammation models. Human RCT evidence is much smaller than the preclinical base.
Proposed mechanism
| Layer | What the research describes |
|---|---|
| MC-receptor independent | Anti-inflammatory effect persists in cells lacking melanocortin receptors. |
| NF-kB | Reported interference with NF-kB activation in stimulated immune cells. |
| Cytokine modulation | Reduces TNF-alpha, IL-1 and other pro-inflammatory mediator output in animal models. |
| Intracellular access | Tripeptide small enough for direct membrane translocation in some models. |
| Gut epithelium | Studied via oral and rectal routes in colitis models. |
Several plausible mechanisms; none is a single dominant pathway. The molecule appears to act through multiple intersecting routes.
Where the evidence sits
Gut inflammation
Animal colitis models report reduced inflammatory scores; small human trials in inflammatory bowel disease contexts exist but are not at registration scale.
Skin and topical
Topical anti-inflammatory effects documented in animal models and some early dermatology studies.
Ocular inflammation
Eye-drop preparations studied in uveitis and dry-eye models.
The interesting feature of KPV is its size: three amino acids is small enough to make oral delivery plausible in a way most peptides cannot manage. This is part of why gut applications have received disproportionate research attention.
The honest framing: a coherent anti-inflammatory signature across preclinical models, a small human evidence base, and no regulatory approval. Curiosity is warranted; clinical certainty is not.
What we know, what's still open
- Anti-inflammatory in animal models: Well-replicated across tissue contexts.
- Mechanism: Plausible but not single-pathway; partly characterised.
- Gut application human evidence: Small, early-stage.
- Topical application evidence: Limited but suggestive.
- Regulatory approval: None in major jurisdictions.
Frequently asked
How does it relate to alpha-MSH?
It is the C-terminal three amino acids of alpha-MSH and retains much of the parent's anti-inflammatory activity without the pigmentation effects.
Can it be taken orally?
Some research uses oral routes given the small molecular size; bioavailability data in humans are not extensive.
Is it the same as BPC-157 in mechanism?
No. Different peptide family, different proposed mechanisms, different (though sometimes overlapping) target tissues.
Is it safe?
Acute toxicity reports are absent in the published literature; long-term human safety not established.
Where to read further
- • Brzoska T et al. Alpha-MSH and KPV anti-inflammatory mechanisms. Endocr Rev 2008.
- • Hiltz ME, Catania A, Lipton JM. KPV in inflammation models. Multiple papers.
- • Dalmasso G et al. PepT1-mediated KPV delivery in colitis. Gastroenterology 2008.